J. Arciniega

发表

Alternative methods and strategies to reduce, refine, and replace animal use for human vaccine post-licensing safety testing: state of the science and future directions

Robert H Levis, W. Casey, T. Finn, 2011 .

Report on the international workshop on alternatives to the murine histamine sensitization test (HIST) for acellular pertussis vaccines: state of the science and the path forward.

W. Stokes, W. Casey, L. Rinckel, 2014, Biologicals : journal of the International Association of Biological Standardization.

The consistency approach for the quality control of vaccines.

Marlies Halder, Keith Redhead, Hans Kreeftenberg, 2008, Biologicals : journal of the International Association of Biological Standardization.

Improving animal welfare and reducing animal use for human vaccine potency testing: state of the science and future directions

Robert H Levis, W. Casey, T. Finn, 2011 .

Target alternative vaccine safety testing strategies for pertussis toxin

J. Arciniega, F. Lynn, Laura Corvette, 2011 .

Bordetella pertussis . characterization of a GroEL-like protein from Purification and immunological

M. Kessel, J. Arciniega, D. Burns, 2022 .

Non-animal replacement methods for human vaccine potency testing: state of the science and future directions

W. Casey, T. Finn, R. Mcfarland, 2011, Procedia in Vaccinology.

Purification and immunological characterization of a GroEL-like protein from Bordetella pertussis

M. Kessel, J. Arciniega, D. Burns, 1991, Infection and immunity.

Safety testing of acellular pertussis vaccines: Use of animals and 3Rs alternatives

J. Arciniega, C. Hendriksen, M. Hoonakker, 2017, Human vaccines & immunotherapeutics.

Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis.

E. Hewlett, I. Onorato, S. Wassilak, 1991, The Journal of infectious diseases.

Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage.

A. Verma, J. Arciniega, L. Sirota, 2013, Biologicals : journal of the International Association of Biological Standardization.

Feasibility of the use of ELISA in an immunogenicity-based potency test of anthrax vaccines.

J. Castelán-Vega, Alicia Jiménez-Alberto, J. Arciniega, 2011, Biologicals : journal of the International Association of Biological Standardization.

Antibodies to Bordetella pertussis adenylate cyclase toxin in neonatal and maternal sera.

E. Hewlett, K. Edwards, J. Arciniega, 1993, FEMS immunology and medical microbiology.

Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin

W. N. Burnette, J. Arciniega, D. Burns, 1991, Infection and immunity.

Human antibody response to the B oligomer of pertussis toxin.

W. N. Burnette, G. Siber, J. Arciniega, 1994, Clinical and diagnostic laboratory immunology.

Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli

W. N. Burnette, J. Arciniega, D. Burns, 1992, Infection and immunity.

Immune response to the B oligomer of pertussis toxin

J. Arciniega, D. Burns, C. Manclark, 1987, Infection and immunity.

Use of Site-Directed Mutagenesis To Model the Effects of Spontaneous Deamidation on the Immunogenicity of Bacillus anthracis Protective Antigen

Miriam M. Ngundi, S. Stibitz, J. Arciniega, 2012, Infection and Immunity.

WHO guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines.

P. Mastrantonio, J. Arciniega, M. Corbel, 1998, Biologicals : journal of the International Association of Biological Standardization.

Reduction of Immunogenicity of Anthrax Vaccines Subjected to Thermal Stress, as Measured by a Toxin Neutralization Assay

J. Castelán-Vega, J. Arciniega, L. Sirota, 2010, Clinical and Vaccine Immunology.

Evaluation of components of X-ray irradiated 7-valent pneumococcal conjugate vaccine and pneumococcal vaccine polyvalent and X-ray and gamma-ray irradiated acellular pertussis component of DTaP vaccine products

J. Arciniega, Chi-Jen Lee, J. May, 2004 .

Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.

J. Arciniega, M. Pombo, L. Wagner, 2005, Vaccine.

Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.

J. Arciniega, L. Sirota, P. Parreiras, 2009, Vaccine.

Manufacturing issues with combining different antigens: a regulatory perspective.

J. Arciniega, L. A. Falk, L. McVittie, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Alternatives to HIST for acellular pertussis vaccines: progress and challenges in replacement.

J Arciniega, L Wagner, R Prymula, 2016, Pharmeuropa bio & scientific notes.

Development and validation of serological methods for human vaccine potency testing: Case study of an anthrax vaccine

J. Arciniega, Rocío I. Domínguez-Castillo, 2011 .

Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice.

J. Arciniega, L. Sirota, Henry Hsu, 2004, Biologicals : journal of the International Association of Biological Standardization.

Immunochemical localization of a region of chaperonin-60 important for productive interaction with chaperonin-10.

M. Kessel, J. Arciniega, D. Burns, 1992, Journal of Biological Chemistry.

Temperature-mediated recombinant anthrax protective antigen aggregate development: Implications for toxin formation and immunogenicity.

J. Arciniega, L. Sirota, Rocío I. Domínguez-Castillo, 2016, Vaccine.